- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02217878
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction (IMPRESSION)
A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The European Society of Cardiology and American Heart Association guidelines recommend use of morphine as a treatment of choice for pain relief in STEMI patients. However, this recommendation, although strong, is only based on expert consensus (class of recommendation I, level of evidence C). Morphine, apart from its analgesic effects, also alleviates the work of breathing and reduces anxiety. On the other hand, despite its favorable analgesic and sedative actions, morphine also exerts adverse effects, which include hypotension, bradycardia, respiratory depression, vomiting and reduction of gastrointestinal motility. Some of the previously listed morphine's side effects could affect the intestinal absorption and thus pharmacokinetics and pharmacodynamics of orally administered drugs which are concomitantly used with morphine. At present, no pharmacokinetic and pharmacodynamic data regarding the concurrent use of morphine and P2Y12 blockers in the STEMI or NSTEMI setting are available. Therefore, evidence-based verification of morphine's influence on pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) could provide a valuable insight in the knowledge regarding modern acute myocardial infarction management.
Predefined subanalysis: aimed to investigate which one of platelet reactivity assessment methods utilized in the study (VASP assay, MEA, LTA, VerifyNow) best reflects concentration of ticagrelor and its active metabolite (AR-C124910XX).
Since there is no reference study examining pharmacokinetics of ticagrelor in STEMI or NSTEMI patients, we decided to perform an internal pilot study of approximately 30 patients (15 patients for each arm) for estimating the final sample size.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Kujawsko-pomorskie
-
Bydgoszcz, Kujawsko-pomorskie, Polen, 85-094
- Cardiology Department, Dr. A. Jurasz University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- provision of informed consent prior to any study specific procedures
- diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction
- male or non-pregnant female, aged 18-80 years old
- provision of informed consent for angiography and PCI
Exclusion Criteria:
- chest pain described by the patient as unbearable or patient's request for analgesics
- prior morphine administration during the current STEMI or NSTEMI
- treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment
- hypersensitivity to ticagrelor
- current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
- active bleeding
- history of intracranial hemorrhage
- recent gastrointestinal bleeding (within 30 days)
- history of coagulation disorders
- platelet count less than <100 x10^3/mcl
- hemoglobin concentration less than 10.0 g/dl
- history of moderate or severe hepatic impairment
- history of major surgery or severe trauma (within 3 months)
- patients considered by the investigator to be at risk of bradycardic events
- second or third degree atrioventricular block during screening for eligibility
- history of asthma or severe chronic obstructive pulmonary disease
- patient required dialysis
- manifest infection or inflammatory state
- Killip class III or IV during screening for eligibility
- respiratory failure
- history of severe chronic heart failure (NYHA class III or IV)
- concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment
- body weight below 50 kg
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Morphine
morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
|
180 mg ladedose
Andre navn:
IV bolus injection
Andre navn:
|
Placebo komparator: Placebo
sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
|
180 mg ladedose
Andre navn:
IV bolus injection
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)
Tidsramme: prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose
|
Exposure to ticagrelor during the first 12 hours after ticagrelor loading dose
|
prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-12h)
Tidsramme: prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose
|
Exposure to ticagrelor metabolite during the first 12 hours after ticagrelor loading dose
|
prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose
|
Maximum Concentration of Ticagrelor
Tidsramme: 12 hours
|
Maximum concentration (Cmax) of ticagrelor
|
12 hours
|
Maximum Concentration of AR-C124910XX
Tidsramme: 12 hours
|
Maximum concentration (Cmax) of AR-C124910XX
|
12 hours
|
Time to Maximum Concentration for Ticagrelor
Tidsramme: 12 hours
|
Time to maximum concentration (Tmax) for ticagrelor
|
12 hours
|
Time to Maximum Concentration for AR-C124910XX
Tidsramme: 12 hours
|
Time to maximum concentration (Tmax) for AR-C124910XX
|
12 hours
|
Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-6h)
Tidsramme: prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose
|
Exposure to ticagrelor during the first 6 hours after ticagrelor loading dose
|
prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose
|
Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-6)
Tidsramme: prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose
|
Exposure to ticagrelor metabolite during the first 6 hours after ticagrelor loading dose
|
prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: prior to the initial ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
prior to the initial ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 30 minutes post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
30 minutes post ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 1 hour post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
1 hour post ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 2 hours post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
2 hours post ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 3 hours post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
3 hours post ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 4 hours post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
4 hours post ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 6 hours post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
6 hours post ticagrelor dose
|
Platelet Reactivity Index Assessed by VASP Assay
Tidsramme: 12 hours post ticagrelor dose
|
Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI >50%)
|
12 hours post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: prior to the initial ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
prior to the initial ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 30 minutes post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
30 minutes post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 1 hour post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
1 hour post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 2 hours post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
2 hours post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 3 hours post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
3 hours post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 4 hours post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
4 hours post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 6 hours post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
6 hours post ticagrelor dose
|
Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
Tidsramme: 12 hours post ticagrelor dose
|
Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC >46 Platelet Arbitrary Aggregation Units)
|
12 hours post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: prior to the initial ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
prior to the initial ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 30 minutes post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
30 minutes post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 1 hour post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
1 hour post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 2 hours post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
2 hours post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 3 hours post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
3 hours post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 4 hours post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
4 hours post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 6 hours post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
6 hours post ticagrelor dose
|
P2Y12 Reaction Units Assessed by VerifyNow
Tidsramme: 12 hours post ticagrelor dose
|
P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU >208)
|
12 hours post ticagrelor dose
|
Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VASP
Tidsramme: 2 hours
|
Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VASP
|
2 hours
|
Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With MEA
Tidsramme: 2 hours
|
Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With MEA
|
2 hours
|
Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VerifyNow
Tidsramme: 2 hours
|
Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VerifyNow
|
2 hours
|
Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VASP
Tidsramme: 12 hours
|
Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VASP
|
12 hours
|
Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With MEA
Tidsramme: 12 hours
|
Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With MEA
|
12 hours
|
Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VerifyNow
Tidsramme: 12 hours
|
Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VerifyNow
|
12 hours
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Prof. Jacek Kubica, MD, PhD, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016 Jan 14;37(3):245-52. doi: 10.1093/eurheartj/ehv547. Epub 2015 Oct 21.
- Kubica J, Adamski P, Ostrowska M, Kozinski M, Obonska K, Laskowska E, Obonska E, Grzesk G, Winiarski P, Paciorek P. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2015 Apr 29;16:198. doi: 10.1186/s13063-015-0724-z.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Iskemi
- Patologiske prosesser
- Nekrose
- Myokardiskemi
- Hjertesykdommer
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Hjerteinfarkt
- Infarkt
- ST Elevation Hjerteinfarkt
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Sentralnervesystemdepressiva
- Agenter fra det perifere nervesystemet
- Analgetika
- Sensoriske systemagenter
- Blodplateaggregasjonshemmere
- Purinergiske P2Y-reseptorantagonister
- Purinergiske P2-reseptorantagonister
- Purinergiske antagonister
- Purinergiske midler
- Analgetika, opioid
- Narkotika
- Ticagrelor
- Morfin
Andre studie-ID-numre
- CMUMK202
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på ST-segment Elevation Hjerteinfarkt
-
Kitasato UniversityRekrutteringAterosklerose | Akutt koronarsyndrom | Stabil angina | Koronar; Iskemisk | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
Capital Medical UniversityFullførtTransradial Approach, Primær PCI, ST-segment Elevation Myocardial InfarctionKina
-
VesalioRekrutteringSegment Elevation Myocardial Infarction (STEMI)Sveits
-
AstraZenecaFullførtHjerteinfarkt | Segment Elevation Myocardial Infarction (STEMI)Australia, Frankrike, Italia, Spania, Storbritannia, Sverige, Tyskland, Ungarn, Danmark, Østerrike, Canada, Nederland, Algerie
-
MallinckrodtTilbaketrukketST-Segment Elevation Myocardial Infraction
-
University of Southern CaliforniaAktiv, ikke rekrutterendeNSTEMI - Ikke-ST Segment Elevation MI | Akutt koronarsyndrom (ACS) | STEMI - ST Elevation Myocardial Infarction (MI) | Ustabil angina (UA)Forente stater
-
Inha University HospitalFullførtST Segment Elevation Hjerteinfarkt | Ikke-ST Segment Elevation MyokardinfarktKorea, Republikken
-
Rigshospitalet, DenmarkRekrutteringST Segment Elevation HjerteinfarktDanmark
-
RenJi HospitalUkjent
-
RenJi HospitalUkjentST Segment Elevation HjerteinfarktKina
Kliniske studier på Ticagrelor
-
Federico II UniversityAdvicePharma GroupFullførtHjerteinfarkt | Koronararteriesykdom | Akutt koronarsyndrom | STEMI | NSTEMIItalia
-
Collegium Medicum w BydgoszczyFullført
-
University of FloridaFullført
-
AstraZenecaParexelFullført
-
University of FloridaAstraZenecaFullført
-
University of FloridaThe Medicines CompanyFullførtKoronararteriesykdomForente stater
-
Centro Hospitalario La ConcepcionRekruttering
-
Sheba Medical CenterFullførtST Elevation Hjerteinfarkt | Akutte koronare syndromerIsrael
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationFullførtAkutt koronarsyndrom | Bivirkning på blodplatehemmende middelItalia, Hellas
-
Bio-innova Co., LtdHar ikke rekruttert ennå